Loading ChartRhythms
Preparing market rhythm analysis...
Preparing market rhythm analysis...
Full Rhythm Report
TECH • Stock • Health Care / Life Sciences Tools & Services
Cross-Horizon Read
TECH's evidence points supportive across the available windows.
Generated 2026-10-05T11:20:00.000Z • Evidence 9e41585b
Price Data
Quote and historical price data are unavailable right now.
ChartRhythms displays a price chart only when real historical time-series data is available. No estimated or synthetic chart is shown.
0–3 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
• Additional dated, company-specific coverage in the 0–3 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
4–21 days
Supporting articles
0
Opposing articles
0
Neutral articles
0
Confidence basis
Supporting evidence
No supporting articles were found in this window.
Opposing evidence
No opposing articles were found in this window.
Catalysts
No specific catalysts were identified in this window.
Risks
No specific risk mentions were identified in this window.
Next proof points
22–90 days
The 22–90 days evidence set currently reads slightly bullish.
Supporting articles
6
Opposing articles
5
Neutral articles
4
Confidence basis
Supporting evidence
• Is Wall Street Bullish or Bearish on Bio-Techne Stock?
• TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
• Bio-Techne Corrects Dividend Announcement
• Bio-Techne Declares Dividend
Help improve this analysis
This feedback is saved locally for the MVP. Later, ChartRhythms can use this feedback to improve the strategy engine.
Important:
ChartRhythms provides source-based market summaries for research and informational purposes only. This is not financial advice and not a recommendation to buy, sell, or hold any security.
• Additional dated, company-specific coverage in the 4–21 days window.
Strengthens if
• Supporting evidence (0) grows relative to opposing evidence (0) in this window.
• No evidence is available for this window is resolved.
Weakens if
• Opposing evidence (0) grows relative to supporting evidence (0) in this window.
Sources in this window (0)
No sources are available for this window yet.
• Bio-Techne (NASDAQ:TECH) Surprises With Q2 CY2026 Sales
Opposing evidence
• Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73
• Bio-Techne Q4 Adj. EPS $0.52, Inline, Sales $321.191M Beat $314.679M Estimate
• Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock?
• What to Expect From Bio-Techne's Next Quarterly Earnings Report
• Q1 Earnings Outperformers: Bio-Techne (NASDAQ:TECH) And The Rest Of The Research Tools & Consumables Stocks
Catalysts
• Is Wall Street Bullish or Bearish on Bio-Techne Stock?
• TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
• Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73
• Bio-Techne Q4 Adj. EPS $0.52, Inline, Sales $321.191M Beat $314.679M Estimate
• Techne (TECH) Q4 Earnings Meet Estimates
Risks
No specific risk mentions were identified in this window.
Next proof points
• Continued coverage in the 22–90 days window confirming the current read.
Strengthens if
• Supporting evidence (6) grows relative to opposing evidence (5) in this window.
• The most recent evidence in this window is not very fresh is resolved.
Weakens if
• Opposing evidence (5) grows relative to supporting evidence (6) in this window.
Showing 8 of 15 sources
Is Wall Street Bullish or Bearish on Bio-Techne Stock?
Yahoo • 2026-08-18 • Bullish
Open via Finnhub →TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
Yahoo • 2026-08-13 • Bullish
Open via Finnhub →Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73
Benzinga • 2026-08-13 • Bearish
Open via Finnhub →Bio-Techne Q4 Adj. EPS $0.52, Inline, Sales $321.191M Beat $314.679M Estimate
Benzinga • 2026-08-12 • Bearish
Open via Finnhub →Bio-Techne (NASDAQ:TECH) Surprises With Q2 CY2026 Sales
Yahoo • 2026-08-12 • Bullish
Open via Finnhub →